Samson-Med
Samson-Med is a Russian full-cycle biopharmaceutical manufacturer that produces polypeptide and protein-based preparations from animal raw materials for domestic institutional and B2B API supply. Its products include Thymalin, Renobrain, Cytochrome C, and Medical Bile, with Renobrain listed in Russia's ZhNVLP.
- Company typePrivate
- Founded2007
- HeadquartersSt. Petersburg, Russia
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Samson-Med does
Samson-Med (OOO Samson-Med) is a Russian full-cycle biopharmaceutical manufacturer headquartered in St. Petersburg that produces biological preparations from animal raw materials, claiming continuity with operations dating to 1937. The legal entity was registered in 2007 and the company was rebranded in October 2018. Its core product portfolio centers on polypeptide and protein-derived pharmaceuticals: Thymalin, an immunostimulant; Renobrain, a nootropic derived from pig brain cortex; Cytochrome C, an antihypoxant; and Medical Bile, a topical analgesic. Renobrain has been included in Russia's Vital and Essential Medicines List (ZhNVLP), anchoring a state-guaranteed demand channel.
The company's business model operates on two revenue tracks. It sells finished preparations directly to Russian healthcare institutions and the broader domestic market, and it acts as an active pharmaceutical ingredient (API) supplier to other drug manufacturers — most notably STADA and Petrovax Pharm — where it serves as a sole supplier for certain APIs. The API contracts embed switching costs through long qualification cycles typical of biopharmaceutical sourcing.
Samson-Med is currently constructing a new full-cycle biopharmaceutical manufacturing plant in the Pushkinsky district of St. Petersburg, signaling a capacity step-up. The company aligns with Russia's Import Substitution Program and has been a special partner of the GMP Conference organized with the Ministry of Industry and Trade. Scientific leadership includes Vladimir Khatskelevich Khavinson as Deputy Director for Scientific Work. Geographic footprint is limited to the Russian domestic market.
Samson-Med firmographics
Firmographics- Name
- Samson-Med
- Legal name
- OOO «Samson-Med»
- Website
- https://samsonmed.ru
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Samson-Med is a Russian full-cycle biopharmaceutical manufacturer that produces polypeptide and protein-based preparations from animal raw materials for domestic institutional and B2B API supply. Its products include Thymalin, Renobrain, Cytochrome C, and Medical Bile, with Renobrain listed in Russia's ZhNVLP.
- Ownership category
- akta.pro rank
Samson-Med industry classification
Industry- Product category
- Biopharmaceutical Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)
Keywords
Where Samson-Med is headquartered
LocationHeadquarters
- HQ city
- St. Petersburg
- HQ country
- Russia
- HQ region
- Europe
Offices1 record
Markets served
Samson-Med business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Supply Chain, Technology or R&D, Marketing or Sales
Revenue model
- Pharmaceutical Product Sales: Sale of proprietary biological preparations from animal raw materials including neurological drugs (Renobrain®), immunostimulants (Thymalin®), antihypoxants (Cytochrome C), and medical bile preparations. Products are sold to healthcare institutions, pharmacies, and through distribution networks across Russia.
- Active Pharmaceutical Ingredients (API) Supply: Supply of active pharmaceutical substances to major pharmaceutical manufacturers including STADA and Petrovax Pharm. The company is the sole supplier of certain APIs for these major producers.
- Contract Manufacturing Services: Provision of contract manufacturing services utilizing full-cycle production capabilities from development through manufacturing of biological preparations from animal raw materials.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Samson-Med product offering
Product offeringCore offering
Samson-Med is a Russian full-cycle biopharmaceutical manufacturer that produces biological preparations from animal raw materials — including polypeptides, enzymes, and tissue extracts — supplied both as finished dosage forms (tablets, capsules, injections, suppositories) and as active pharmaceutical substances (APIs). The company also offers contract manufacturing of solid dosage forms for partner pharmaceutical companies.
Product overview
Samson-Med is a Russian biopharmaceutical company operating a full-cycle production model — from development and research through to manufacturing of biological preparations from animal-derived raw materials. The company also provides contract manufacturing services. Its product portfolio consists of finished dosage forms (Renobrain® for neurological therapy, Cytochrome C as an antihypoxant, Thymalin® as an immunostimulant, and Medical Bile for topical analgesic use) as well as active pharmaceutical substances (APIs) supplied to other pharmaceutical manufacturers. The company positions itself as a full-cycle manufacturer contributing to Russia's import substitution program in pharmaceuticals.
Differentiator
Problem solved
Functional benefit
Brands
- Renobrain®: Neurological drug for therapy of stroke and chronic cerebral ischemia, containing polypeptides of bovine brain cortex.
- Timelin®
- Cytochrome C
Products and services
- Renobrain®
Quantifiable outcome
- More than 450,000 stroke cases registered annually in Russia represent significant addressable market for neurological preparations.
- +2 more outcomes
Companies that use Samson-Med
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
Samson-Med technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Samson-Med partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered strategic and core.
- Ministry of Industry and Trade of the Russian FederationstrategicThe Ministry of Industry and Trade of the Russian Federation organizes key pharmaceutical industry events including GMP conferences. Samson-Med participated as a special partner of the VI All-Russian GMP Conference, contributing to industry development discussions and regulatory alignment.
- Import Substitution ProgramstrategicSamson-Med contributes to the President's import substitution program as a full-cycle domestic manufacturer, developing high-tech production where not only the final product but also components and materials along the technological chain have domestic origin.
- STADAcoreSTADA is a major international pharmaceutical company operating in Russia. Samson-Med is the sole supplier of certain active pharmaceutical ingredients (APIs) to STADA, representing a critical B2B partnership for API supply.
- Petrovax PharmcorePetrovax Pharm is a major Russian pharmaceutical manufacturer. Samson-Med supplies active pharmaceutical substances to Petrovax Pharm, positioning the company as a key API supplier in the Russian pharmaceutical supply chain.
Scale indicators5 records
Recent moves8 records
Expansion highlights4 records
Samson-Med competitors and assessment
Company assessmentDirect peers
- Sotex: Russian pharmaceutical manufacturer of generic and specialty finished dosage forms, supplying hospitals and pharmacies across Russia. Comparable to Samson-Med as a domestic finished-dose producer with overlapping distribution channels and institutional customers.
- Geropharm: Russian pharmaceutical manufacturer of peptide-based and biological preparations, including Cortexin® (the direct analog of Samson-Med's Renobrain®). Direct competitor in the neurological polypeptide segment and animal-derived biologics space in Russia.
- Petrovax Pharm: Major Russian pharmaceutical manufacturer that is also a customer of Samson-Med (API supply). Comparable as a Russia-based finished-dose producer with overlapping therapeutic focuses and as a participant in the same domestic pharmaceutical supply chain.
- NPO Microgen: Russian manufacturer of biological products including immunobiological preparations and APIs. Comparable to Samson-Med as a domestic Russian producer of biologicals and APIs derived from natural sources, sharing similar regulatory and supply-chain dynamics.
- Valenta Pharm: Russian pharmaceutical manufacturer producing branded finished dosage forms across therapeutic categories including neurology and immunology. Comparable to Samson-Med as a domestic Russian finished-dose producer with similar B2B distribution through healthcare institutions.
- Materia Medica: Russian pharmaceutical company developing and producing innovative finished dosage forms, with a focus on specialty and neurological therapies. Comparable to Samson-Med as a domestic Russian manufacturer with overlapping therapeutic categories and B2B sales models.
Broad incumbents
- Biocad: Russian biotechnology company developing and manufacturing biological and biosimilar products. Comparable to Samson-Med as a domestically-focused Russian biopharma with biological manufacturing capabilities, though concentrated in biotech/biosimilars rather than animal-derived peptides.
- Veropharm: Russian pharmaceutical manufacturer producing a wide range of generic and specialty finished dosage forms. Comparable to Samson-Med as a Russian finished-dose producer supplying institutional buyers, although with a broader and less specialized portfolio.
- Pharmstandard: One of the largest pharmaceutical manufacturers in Russia, producing a broad portfolio of finished dosage forms across multiple therapeutic areas. Comparable to Samson-Med as a Russian finished-dose manufacturer, though with a much broader and less specialized portfolio.
- STADA: International pharmaceutical company with significant Russia operations. Acts as a customer of Samson-Med for API supply, making it a comparable finished-dose manufacturer with overlapping product strategies in the Russian market.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Samson-Med social profiles
Digital presenceSamson-Med financial estimates
Financial estimateRevenue estimate
Valuation estimate
Samson-Med leadership team
Management profileNumber of profiles
Profiles1 record
Samson-Med funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Samson-Med M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Samson-Med
What does Samson-Med do?
Samson-Med is a Russian full-cycle biopharmaceutical manufacturer that produces biological preparations from animal raw materials — including polypeptides, enzymes, and tissue extracts — supplied both as finished dosage forms (tablets, capsules, injections, suppositories) and as active pharmaceutical substances (APIs). The company also offers contract manufacturing of solid dosage forms for partner pharmaceutical companies.
Is Samson-Med a public or private company?
Samson-Med is a private company. It is classified as unknown and is currently operating.
When was Samson-Med founded?
Samson-Med was founded in 2007. It employs 1 to 10 people.
Where is Samson-Med based?
Samson-Med is headquartered in St. Petersburg, Russia, in the Europe region.
How does Samson-Med make money?
Three revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are active Pharmaceutical Ingredients (API) Supply and contract Manufacturing Services.
Who are Samson-Med's main competitors?
Direct peers on record are Sotex, Geropharm, Petrovax Pharm, NPO Microgen, Valenta Pharm and Materia Medica. Broad incumbents are Biocad, Veropharm, Pharmstandard and STADA.
Does Samson-Med have an API?
No public API is recorded for Samson-Med.
What industry is Samson-Med in?
Samson-Med's product category is Biopharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing. Its NAICS code is 325412 and its SIC code is 2834.